Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Ernexa Therapeutics announced that new preclinical data for its lead oncology program ERNA-101 were selected for a Flash Talk at the Next-Generation Cancer Therapeutics meeting co-hosted by Nature Conferences and MD Anderson Cancer Center, October 6-8, 2026 in Houston. In preclinical models of high-grade serous ovarian cancer, ERNA-101 promoted immune cell recruitment, drove significant tumor regression and enhanced survival, and combined with PD-1 blockade achieved complete tumor control and durable responses in the majority of treated animals.
Key figures
- Drug Name
- ERNA-101
- Phase Of Trial
- Preclinical
- First clinical data
- Q4 2027 expected
- Ind plan submission
- Q4 2026 planned
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.